Finanzen von ProQR Therapeutics NV (PRQR)PRQRProQR Therapeutics NV

Evaluating the bottom line, ProQR Therapeutics NV maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -100.72%, while the net margin is -99.65%. These profitability ratios, combined with a Return on Equity (ROE) of -57.40%, provide a clear picture of how effectively PRQR converts its operational activities into shareholder value.

In the context of the broader market, PRQR competes directly with industry leaders such as AKBA and ADCT. With a market capitalization of $198.98M, it holds a significant position in the sector. When comparing efficiency, PRQR's gross margin of 100.00% stands against AKBA's 80.50% and ADCT's 88.68%. Such benchmarking helps identify whether ProQR Therapeutics NV is trading at a premium or discount relative to its financial performance.

ProQR has a gross margin of 100%, but it has been reporting significant net losses, with a net income loss of €13,383,000 in Q1 2026. The forward P/E ratio is not applicable due to negative earnings.